05:06 AM EDT, 10/07/2024 (MT Newswires) -- GE HealthCare Technologies ( GEHC ) said Monday it has completed its phase 1 clinical development program for a manganese-based macrocyclic magnetic resonance imaging contrast agent.

Results of the trial showed the contrast agent was well tolerated with no serious adverse events and dose-limiting toxicities, the company said.

"MRI contrast agents, which are typically gadolinium-based, are used to enhance visualization of abnormal structures or lesions and to aid differentiation between healthy and pathological tissue," GE HealthCare ( GEHC ) said.

Price: 89.60, Change: -1.82, Percent Change: -1.99